222 related articles for article (PubMed ID: 32893084)
1. Melatonin: A Potential Therapeutic Option for Breast Cancer.
Kong X; Gao R; Wang Z; Wang X; Fang Y; Gao J; Reiter RJ; Wang J
Trends Endocrinol Metab; 2020 Nov; 31(11):859-871. PubMed ID: 32893084
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effects of melatonin on breast cancer].
Jiang Z; Ma F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 42(3):346-351. PubMed ID: 28364111
[TBL] [Abstract][Full Text] [Related]
3. Melatonin: an inhibitor of breast cancer.
Hill SM; Belancio VP; Dauchy RT; Xiang S; Brimer S; Mao L; Hauch A; Lundberg PW; Summers W; Yuan L; Frasch T; Blask DE
Endocr Relat Cancer; 2015 Jun; 22(3):R183-204. PubMed ID: 25876649
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of melatonin anticancer effects.
Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
[TBL] [Abstract][Full Text] [Related]
5. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.
Blask DE; Hill SM; Dauchy RT; Xiang S; Yuan L; Duplessis T; Mao L; Dauchy E; Sauer LA
J Pineal Res; 2011 Oct; 51(3):259-69. PubMed ID: 21605163
[TBL] [Abstract][Full Text] [Related]
6. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer.
Hill SM; Blask DE; Xiang S; Yuan L; Mao L; Dauchy RT; Dauchy EM; Frasch T; Duplesis T
J Mammary Gland Biol Neoplasia; 2011 Sep; 16(3):235-45. PubMed ID: 21773809
[TBL] [Abstract][Full Text] [Related]
7. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.
Blask DE; Dauchy RT; Brainard GC; Hanifin JP
Integr Cancer Ther; 2009 Dec; 8(4):347-53. PubMed ID: 20042410
[TBL] [Abstract][Full Text] [Related]
8. Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
Goyal R; Gupta T; Bal A; Sahni D; Singh G
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):518-523. PubMed ID: 31290783
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions.
Cos S; González A; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ
Cancer Detect Prev; 2006; 30(2):118-28. PubMed ID: 16647824
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal.
Xiang S; Dauchy RT; Hauch A; Mao L; Yuan L; Wren MA; Belancio VP; Mondal D; Frasch T; Blask DE; Hill SM
J Pineal Res; 2015 Aug; 59(1):60-9. PubMed ID: 25857269
[TBL] [Abstract][Full Text] [Related]
11. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer.
Molis TM; Spriggs LL; Jupiter Y; Hill SM
J Pineal Res; 1995 Mar; 18(2):93-103. PubMed ID: 7629697
[TBL] [Abstract][Full Text] [Related]
12. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin.
Ram PT; Yuan L; Dai J; Kiefer T; Klotz DM; Spriggs LL; Hill SM
J Pineal Res; 2000 May; 28(4):210-8. PubMed ID: 10831156
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.
Xiang S; Dauchy RT; Hoffman AE; Pointer D; Frasch T; Blask DE; Hill SM
J Pineal Res; 2019 Sep; 67(2):e12586. PubMed ID: 31077613
[TBL] [Abstract][Full Text] [Related]
14. The Galphai and Galphaq proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation.
Lai L; Yuan L; Chen Q; Dong C; Mao L; Rowan B; Frasch T; Hill SM
J Pineal Res; 2008 Nov; 45(4):476-88. PubMed ID: 18705646
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
Ram PT; Kiefer T; Silverman M; Song Y; Brown GM; Hill SM
Mol Cell Endocrinol; 1998 Jun; 141(1-2):53-64. PubMed ID: 9723886
[TBL] [Abstract][Full Text] [Related]
16. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
Girgert R; Hanf V; Emons G; Gründker C
J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
[TBL] [Abstract][Full Text] [Related]
17. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.
Tamarkin L; Danforth D; Lichter A; DeMoss E; Cohen M; Chabner B; Lippman M
Science; 1982 May; 216(4549):1003-5. PubMed ID: 7079745
[TBL] [Abstract][Full Text] [Related]
18. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.
Dauchy RT; Xiang S; Mao L; Brimer S; Wren MA; Yuan L; Anbalagan M; Hauch A; Frasch T; Rowan BG; Blask DE; Hill SM
Cancer Res; 2014 Aug; 74(15):4099-110. PubMed ID: 25062775
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer therapy based on melatonin.
Sanchez-Barcelo EJ; Mediavilla MD; Alonso-Gonzalez C; Rueda N
Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):108-16. PubMed ID: 22369716
[TBL] [Abstract][Full Text] [Related]
20. Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.
Mao L; Summers W; Xiang S; Yuan L; Dauchy RT; Reynolds A; Wren-Dail MA; Pointer D; Frasch T; Blask DE; Hill SM
Mol Cancer Res; 2016 Nov; 14(11):1159-1169. PubMed ID: 27535706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
